Restricted accessResearch articleFirst published online 2013-7
Hypofractionated intensity-modulated radiotherapy using simultaneous integrated boost technique with concurrent and adjuvant temozolomide for glioblastoma
We assessed the therapeutic efficacy of combined hypofractionated intensity-modulated radiotherapy with temozolomide in patients with primary glioblastoma.
Methods and study design
Thirty-nine patients with histologically confirmed glioblastoma were accrued. Using the simultaneous integrated boost technique, a dose of 50 Gy in 5-Gy fractions was applied to the gross tumor volume, together with 40 Gy in 4-Gy fractions and 30 Gy in 3-Gy fractions to the 1- and 2-cm margins from the gross tumor volume, respectively. Patients were also treated with concurrent temozolomide during intensity-modulated radiotherapy, followed by six cycles of adjuvant temozolomide.
Results
Median follow-up was 16.8 months (range, 4.3–54.3). Tumor progression was observed in 28 patients (71.8%), and the median time to progression was 6.8 months. Median survival was 16.8 months, and it was affected significantly by the extent of surgery. During adjuvant temozolomide treatment, 3 patients (9.7%) developed grade 3–4 hematologic or hepatic toxicity. Radiation necrosis developed in 7 patients (17.9%) and massive necrosis, requiring emergency surgery, in 1 patient (2.6%).
Conclusions
The regimen of hypofractionated intensity-modulated radiotherapy with temozolomide showed a relatively good outcome in patients with glioblastoma. Further studies are required to define the optimal fraction size for glioblastoma using this highly sophisticated radiation technique.
ChanJ.L., LeeS.W., FraassB.A., NormolleD.P., GreenbergH.S., JunckL.R., GebarskiS.S., SandlerH.M.: Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy.J Clin Oncol, 20: 1635–1642, 2002.
2.
SelkerR.G., ShapiroW.R., BurgerP., BlackwoodM.S., ArenaV.C., GilderJ.C., MalkinM.G., MealeyJ.J.Jr., NealJ.H., OlsonJ., RobertsonJ.T., BarnettG.H., BloomfieldS., AlbrightR., HochbergF.H., HiesigerE., GreenS.: The Brain Tumor Cooperative Group NIH Trial 87–01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine.Neurosurgery, 51: 343–357, 2002.
3.
SouhamiL., SeiferheldW., BrachmanD., PodgorsakE.B., Werner-WasikM., LustigR., SchultzC.J., SauseW., OkunieffP., BucknerJ., ZamoranoL., MehtaM.P., CurranW.J.Jr.: Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93–05 protocol.Int J Radiat Oncol Biol Phys, 60: 853–860, 2004.
4.
Werner-WasikM., ScottC.B., NelsonD.F., GasparL.E., MurrayK.J., FischbachJ.A., NelsonJ.S., WeinsteinA.S., CurranW.J.Jr.: Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83–02.Cancer, 77: 1535–1543, 1996.
5.
BudachW., GioiosoD., TaghianA., StuschkeM., SuitH.D.: Repopulation capacity during fractionated irradiation of squamous cell carcinomas and glioblastomas in vitro.Int J Radiat Oncol Biol Phys, 39: 743–750, 1997.
6.
Panet-RaymondV., SouhamiL., RobergeD., KavanP., ShakibniaL., MuanzaT., LambertC., LeblancR., Del MaestroR., GuiotM.C., ShenoudaG.: Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.Int J Radiat Oncol Biol Phys, 73: 473–478, 2009.
StuppR., HegiM.E., MasonW.P., van den BentM.J., TaphoornM.J., JanzerR.C., LudwinS.K., AllgeierA., FisherB., BelangerK., HauP., BrandesA.A., GijtenbeekJ., MarosiC., VechtC.J., MokhtariK., WesselingP., VillaS., EisenhauerE., GorliaT., WellerM., LacombeD., CairncrossJ.G., MirimanoffR.O.: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.Lancet Oncol, 10: 459–466, 2009.
12.
CurranW.J.Jr., ScottC.B., HortonJ., NelsonJ.S., WeinsteinA.S., FischbachA.J., ChangC.H., RotmanM., AsbellS.O., KrischR.E., NelsonD.F.: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.J Natl Cancer Inst, 85: 704–710, 1993.
MorgantiA.G., BalducciM., SalvatiM., EspositoV., RomanelliP., FerroM., CalistaF., DigesuC., MacchiaG., IaniriM., DeodatoF., CillaS., PiermatteiA., ValentiniV., CelliniN., CantoreG.P.: A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma.Int J Radiat Oncol Biol Phys, 77: 92–97, 2010.
18.
GutinP.H., PradosM.D., PhillipsT.L., WaraW.M., LarsonD.A., LeibelS.A., SneedP.K., LevinV.A., WeaverK.A., SilverP., LambornK., LambS., HamB.: External irradiation followed by an interstitial high activity iodine-125 implant “boost” in the initial treatment of malignant gliomas: NCOG study 6G-82–2.Int J Radiat Oncol Biol Phys, 21: 601–606, 1991.
19.
StummerW., PichlmeierU., MeinelT., WiestlerO.D., ZanellaF., ReulenH.J.: Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial.Lancet Oncol, 7: 392–401, 2006.
20.
HegiM.E., DiserensA.C., GorliaT., HamouM.F., de TriboletN., WellerM., KrosJ.M., HainfellnerJ.A., MasonW., MarianiL., BrombergJ.E., HauP., MirimanoffR.O., CairncrossJ.G., JanzerR.C., StuppR.: MGMT gene silencing and benefit from temozolomide in glioblastoma.N Engl J Med, 352: 997–1003, 2005.
